Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction
Renin–angiotensin–aldosterone system inhibitors (RAASi) are known to improve outcomes in patients who have heart failure with reduced ejection fraction (HFrEF). To reduce mortality in these patients, RAASi should be uptitrated to the maximally tolerated dose. However, RAASi may also cause hyperkalem...
Saved in:
| Main Authors: | Giuseppe MC Rosano, Ilaria Spoletini, Cristiana Vitale, Stefan Agewall |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2019-11-01
|
| Series: | Cardiac Failure Review |
| Online Access: | https://www.cfrjournal.com/articles/Hyperkalemia-Renin-Angiotensin-Aldosterone-System-Inhibitors-HFrEF |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impaired aldosterone response to potassium and hyperkalemia in patients receiving a renin-angiotensin-aldosterone system inhibitor
by: Miyeon Kim, et al.
Published: (2025-05-01) -
Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
by: Davide Stolfo, et al.
Published: (2019-05-01) -
Sodium Zirconium Cyclosilicate for Renin–Angiotensin–Aldosterone System Inhibitor Optimization in Patients with Heart Failure with Reduced Ejection Fraction: A Retrospective Analysis
by: Rhys Williams, et al.
Published: (2024-11-01) -
The Renin–Angiotensin–Aldosterone System and Coronavirus Disease 2019
by: Eliecer Coto, et al.
Published: (2021-03-01) -
Effect of combination antihypertensive therapy, including renin-angiotensin-aldosterone system inhibitors, on oxidative stress and arterial remodeling in hypertensive patients with heart failure with preserved ejection fraction
by: Z. M. Akhilgova, et al.
Published: (2021-06-01)